Technical Analysis for XOMA - XOMA Corporation

Grade Last Price % Change Price Change
A 30.38 0.60% 0.18
XOMA closed up 0.6 percent on Friday, November 1, 2024, on 44 percent of normal volume.
Earnings due: Nov 5
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.60%
Calm After Storm Range Contraction 0.60%
Multiple of Ten Bullish Other 0.60%
Inside Day Range Contraction 0.60%
Gapped Up Strength 0.60%
Overbought Stochastic Strength 0.60%
Stochastic Sell Signal Bearish 1.74%
20 DMA Support Bullish 1.74%

   Recent Intraday Alerts

Alert Time
Gap Down Closed about 23 hours ago
Reversed from Down about 23 hours ago
10 DMA Support about 23 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 23 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

XOMA Corporation Description

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Immune System Infectious Diseases Diabetes Antibodies Monoclonal Antibodies Antibody Prostate Cancer Hypertension Non Small Cell Lung Cancer Cardiovascular Disease Allergy Small Cell Lung Cancer Multiple Myeloma Vascular Disease Osteoarthritis Acne Metabolic Disorders Platform Technologies Inflammatory Uveitis Botulism Human Monoclonal Antibodies Antibody Product Non Infectious Uveitis

Is XOMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.93
52 Week Low 14.27
Average Volume 21,965
200-Day Moving Average 25.54
50-Day Moving Average 28.27
20-Day Moving Average 28.95
10-Day Moving Average 29.78
Average True Range 1.48
RSI (14) 58.33
ADX 20.23
+DI 21.67
-DI 14.47
Chandelier Exit (Long, 3 ATRs) 27.48
Chandelier Exit (Short, 3 ATRs) 30.37
Upper Bollinger Bands 31.43
Lower Bollinger Band 26.47
Percent B (%b) 0.79
BandWidth 17.12
MACD Line 0.76
MACD Signal Line 0.61
MACD Histogram 0.1518
Fundamentals Value
Market Cap 349 Million
Num Shares 11.5 Million
EPS -2.81
Price-to-Earnings (P/E) Ratio -10.81
Price-to-Sales 53.15
Price-to-Book 2.26
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.57
Resistance 3 (R3) 31.45 30.94 31.37
Resistance 2 (R2) 30.94 30.64 31.00 31.30
Resistance 1 (R1) 30.66 30.45 30.80 30.78 31.24
Pivot Point 30.15 30.15 30.22 30.21 30.15
Support 1 (S1) 29.87 29.85 30.01 29.99 29.52
Support 2 (S2) 29.36 29.66 29.42 29.46
Support 3 (S3) 29.08 29.36 29.39
Support 4 (S4) 29.20